Final report

LDR 01318nam a22003611 4500
001 001106658
003 MiAaHDL
005 20221206000000.0
006 m d
007 cr bn ---auaua
008 890623s1969 dcu b 00000 eng d
010 ‡a72600933 //r88
035 ‡a(MiU)990011066580106381
035 ‡asdr-miu.990011066580106381
035 ‡asdr-ucbk.b133470799
035 ‡z(MiU)MIU01000000000000001106658-goog
035 ‡a(OCoLC)7549
035 ‡a(SAZTEC)046802030
035 ‡a(SAZTEC)046802020
035 ‡a(SAZTEC)046802010
035 ‡a(CaOTULAS)175982345
035 ‡z(MiU)Aleph001106658
040 ‡aDLC ‡cDLC
043 ‡an-us---
050 0 0 ‡aHD7103.5.U5 ‡bA52
082 ‡a368.4/26
110 1 ‡aUnited States. ‡bTask Force on Prescription Drugs.
245 0 0 ‡aFinal report.
260 ‡aWashington, ‡bOffice of the Secretary, U.S. Dept. of Health, Education, and Welfare; [for sale by the Supt. of Docs., U.S. Govt. Print. Off.] ‡c1969.
300 ‡axxii, 86 p. ‡c26 cm.
500 ‡aUpdates material initially presented in interim reports.
500 ‡aCommonly known as the Lee report.
504 ‡aBibliographical footnotes.
538 ‡aMode of access: Internet.
650 0 ‡aPharmaceutical industry ‡zUnited States.
650 0 ‡aPharmaceutical services insurance ‡zUnited States.
740 0 ‡aLee report on prescription drugs.
899 ‡a39015009549653
CID ‡a001106658
DAT 0 ‡a19890623000000.0 ‡b20221206000000.0
DAT 1 ‡a20221209060805.0 ‡b2023-08-05T17:45:05Z
DAT 2 ‡a2023-08-05T17:30:02Z ‡b2014-02-05T21:00:04Z
CAT ‡aSDR-MIU ‡cmiu ‡dALMA ‡lprepare.pl-004-008
FMT ‡aBK
HOL ‡0sdr-miu.990011066580106381 ‡aMiU ‡bSDR ‡cMIU ‡f001106658 ‡pmdp.39015009549653 ‡sMIU ‡1990011066580106381
974 ‡bMIU ‡cMIU ‡d20230805 ‡sgoogle ‡umdp.39015009549653 ‡y1969 ‡rpd ‡qexp
974 ‡bUC ‡cUCBK ‡d20210211 ‡sberkeley ‡uucbk.ark:/28722/h24m91j4h ‡y1969 ‡ric ‡qbib ‡tUS bib date1 >= 1929